| Source: |
| Type: |
| Toxicity |
| Breast Cancer |
| 1078- | And, | Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs | - | in-vivo, | BC, | MCF-7 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | BT549 | - | in-vitro, | BC, | MDA-MB-361 |
| 1999- | Api, | doxoR, | Apigenin ameliorates doxorubicin-induced renal injury via inhibition of oxidative stress and inflammation |
| - | in-vitro, | Nor, | NRK52E | - | in-vitro, | Nor, | MPC5 | - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 1368- | Ash, | Cisplatin, | Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’ |
| - | in-vitro, | Colon, | HT-29 | - | in-vitro, | BC, | MDA-MB-231 |
| 1447- | Bos, | Boswellia carterii n-hexane extract suppresses breast cancer growth via induction of ferroptosis by downregulated GPX4 and upregulated transferrin |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vivo, | BC, | 4T1 | - | in-vitro, | Nor, | MCF10 |
| 5991- | Chit, | Chitosan-Based Nanoencapsulated Essential Oils: Potential Leads against Breast Cancer Cells in Preclinical Studies |
| - | Review, | BC, | NA |
| 6070- | CHL, | Preclinical evaluation of sodium copper chlorophyllin: safety, pharmacokinetics, and therapeutic potential in breast cancer chemotherapy and cyclophosphamide-induced bladder toxicity |
| - | in-vitro, | BC, | 4T1 |
| 951- | DHA, | Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 660- | EGCG, | FA, | Epigallocatechin-3-gallate Delivered in Nanoparticles Increases Cytotoxicity in Three Breast Carcinoma Cell Lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 837- | Gra, | Quantitative assessment of the relative antineoplastic potential of the n-butanolic leaf extract of Annona muricata Linn. in normal and immortalized human cell lines |
| - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Nor, | WRL68 | - | in-vitro, | Nor, | HaCaT |
| 851- | Gra, | Antiproliferation Activity and Apoptotic Mechanism of Soursop (Annona muricata L.) Leaves Extract and Fractions on MCF7 Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | CV1 |
| 2456- | MET, | Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vivo, | NA, | NA |
| 501- | MF, | Low Intensity and Frequency Pulsed Electromagnetic Fields Selectively Impair Breast Cancer Cell Viability |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | MCF10 |
| 512- | MF, | Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | FF95 |
| 2046- | PB, | Sodium butyrate promotes apoptosis in breast cancer cells through reactive oxygen species (ROS) formation and mitochondrial impairment |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | Nor, | MCF10 |
| 5040- | SAS, | Structure-Activity-Relationship-Aided Design and Synthesis of xCT Antiporter Inhibitors |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | BC, | MCF-7 |
| 5039- | SAS, | Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer |
| - | vitro+vivo, | BC, | NA |
| 4473- | SeNPs, | Anti-cancerous effect and biological evaluation of green synthesized Selenium nanoparticles on MCF-7 breast cancer and HUVEC cell lines |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HUVECs |
| 1430- | SFN, | Sulforaphane bioavailability and chemopreventive activity in women scheduled for breast biopsy |
| - | Trial, | BC, | NA |
| 2007- | SK, | Shikonin Directly Targets Mitochondria and Causes Mitochondrial Dysfunction in Cancer Cells |
| - | in-vitro, | lymphoma, | U937 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SkBr3 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | OS, | U2OS | - | NA, | Nor, | RPE-1 |
| 977- | SK, | A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HMEC |
| 3421- | TQ, | Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer |
| - | Analysis, | Nor, | NA | - | in-vivo, | Nor, | NA | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | HaCaT |
| 4840- | Uro, | Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer |
| - | vitro+vivo, | BC, | NA |
| 610- | VitC, | Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues |
| - | in-vitro, | lymphoma, | JPL119 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | HS587T | - | in-vitro, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:4 Cells:% prod#:% Target#:1025 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid